In the News
Hyperglycemia common, linked with poor outcomes in general surgery patients
More than 6% of 282,131 general surgery patients had HbA1c levels in the diabetic range but did not have a diabetes diagnosis, an analysis of a U.S. database found.
Physical activity may help address hyperglycemia in type 1 diabetes
Exercise bouts of 10 to 30 minutes led to a mean change of −2.2 mmol/L (−39.6 mg/dL) in glucose level compared with no activity in patients with type 1 diabetes, a study found.
Natriuretic peptide levels predicted heart failure risk in diabetes
A test manufacturer's retrospective analysis of type 1 and 2 diabetes patients who underwent natriuretic peptide testing found that elevated levels of terminal pro-brain natriuretic peptide or B-type natriuretic peptide were associated with development of heart failure and death.
MKSAP quiz: Hyperglycemic crisis
This month's quiz asks readers to evaluate a 68-year-old man with type 2 diabetes, elevated blood glucose levels, and symptoms of nausea, vomiting, and dyspnea.
Spotlight on SGLT-2 inhibitors and the kidneys
Two meta-analyses of sodium-glucose cotransporter-2 (SGLT-2) inhibitors suggested that the class offers benefits to patients at a wider range of kidney functions than targeted by current recommendations, and a third study offered a score for identifying patients who would benefit.
Gastrointestinal effects compared across GLP-1 drugs in real-world study
Patients who took the glucagon-like peptide-1 (GLP-1) receptor agonists dulaglutide or semaglutide or the GLP-1/glucose-dependent insulinotropic polypeptide receptor agonist tirzepatide had similar rates of adverse gastrointestinal events, a database study found.
Patients with hyperglycemia during ICU stay have higher risk of postdischarge diabetes
Critical illness-associated hyperglycemia is associated with a 4.1% risk of new-onset diabetes within five years of discharge, compared to 1.8% in patients who didn't develop high blood glucose levels in the ICU, a Swedish study found.
Oral semaglutide gets new indication from FDA
The medication is now indicated to reduce the risk of major adverse cardiovascular events such as cardiovascular death, heart attack, or stroke in adults with type 2 diabetes who are at high risk for these events.